More on Rifampin Prophylaxis against Haemophilus influenzae b in Day-Care Facilities

Claire V. Broome, Edward A. Mortimer, Samuel L. Katz, David W. Fleming, Allen W. Hightower, Michael T. Osterholm, Trudy V. Murphy

Research output: Contribution to journalLetter

2 Scopus citations

Abstract

To the Editor: A Special Report in the May 7 issue1 by some of the members of the Immunization Practices Advisory Committee (ACIP) and staff members of the Centers for Disease Control, was not a formal statement by the ACIP. Rather, it was a discussion of the rationale for the ACIP's recommendations on the use of rifampin chemoprophylaxis for the prevention of secondary cases of Haemophilus influenzae b disease.1 In that article we raised issues pertaining to the Minnesota and Texas studies23 in an attempt to explain differences in the occurrence of secondary H. influenzae b disease in day-care facilities.

Original languageEnglish (US)
Pages (from-to)48-49
Number of pages2
JournalNew England Journal of Medicine
Volume318
Issue number1
DOIs
StatePublished - Jan 7 1988
Externally publishedYes

Fingerprint Dive into the research topics of 'More on Rifampin Prophylaxis against Haemophilus influenzae b in Day-Care Facilities'. Together they form a unique fingerprint.

  • Cite this

    Broome, C. V., Mortimer, E. A., Katz, S. L., Fleming, D. W., Hightower, A. W., Osterholm, M. T., & Murphy, T. V. (1988). More on Rifampin Prophylaxis against Haemophilus influenzae b in Day-Care Facilities. New England Journal of Medicine, 318(1), 48-49. https://doi.org/10.1056/NEJM198801073180112